Cosmetic Patents

Day 22 handover (a) CS-005 avobenzone origin patent USPTO direct search executed. Wikipedia en Avobenzone records only the single line 'patented in 1973' with no number, and PubChem CID 51040 / Pharmacompass / Smartskincare (smartskincare.com) / ScienceDirect Avobenzone overview / Univar Solutions / The Cosmetic Chemist / MakingCosmetics / CosDNA / Wikidoc / EWG Skin Deep / Incidecoder / Specialchem also lack the 1973 origin patent number. The Wikipedia patent citation is an incomplete OpenURL with 'rft.cc=US&rft.number=0' — the number field is empty. AI-generated candidate numbers (CH561168A5, CH570454A5, US3920734, DE2354187, likely Search AI Overview output) all return zero direct hits via WebSearch and patents.google.com is Captcha-blocked, so entity verification is impossible. The assignee transition is Roure Bertrand Dupont SA (Société Anonyme, France/Paris, possibly 1971-12-16 CH priority) → 1991 Givaudan and Roure merger → mid-1990s Givaudan-Roure → 2000 spinoff from Roche to DSM Nutritional Products → 2010s and later DSM holds the Parsol® 1789 trademark (currently dsm-firmenich.com manages BMI). FDA OTC approval was 1988 (US market entry 10 years after EU 1978 approval). USPTO Patent Public Search and Espacenet Worldwide Search both require interactive UIs; curl/WebFetch hits browser rendering, Captcha, or REST 403 access denial. Following Day 22 ep80 CS-010 Sansho Seiyaku kojic acid (J-PlatPat wall) and Day 23 ep83 CS-004 Nivea Lifschütz (DPMA wall), confirmed as cosmetic form-3 information wall excavation #3. This memo records the third instance of the finding 'origin patent number lies behind an information wall' and leaves USPTO Patent Public Search interactive search (assignee=Roure Bertrand Dupont, 1971-1974 priority) or DSM/Givaudan direct inquiry as the next action.

Day 22 handover (a) CS-004 Nivea/Eucerit origin patent DPMA direct search executed. Lifschütz's 1902 DRP number is not recorded in any of: (1) Beiersdorf official About Us page, (2) Beiersdorf official Chronicle 12 PDF (5.7 MB, pdftotext extracted body and captions), (3) Wikipedia en Eucerin / de Isaac Lifschütz, (4) German Chemie-Schule Eucerit/Lifschütz entries, (5) German PharmaWiki Wollwachsalkohole, (6) German Jüdische Allgemeine 'Der Doktor aus Pinsk,' (7) Beiersdorf official Eucerin Brand History. The Beiersdorf Chronicle 12 PDF contains a caption explainer '1) Patent number — This number precisely identifies the patent and allows it to be referenced at the patent office. Dr. Isaac Lifschütz laid the foundation for dermatological skin care with the patent for a method of producing highly water-absorbent ointment bases.' — but the actual number itself does not appear in body text. Early-1900s DRP records are outside DPMA DEPATISnet's electronic-coverage scope. Espacenet and Google Patents DE coverage centers on 1920+. AI-generated candidate numbers (DRP 132307 / DRP 154959 / DRP 171146, etc.) cannot be verified via WebSearch (patents.google.com 503/Captcha, Espacenet REST 403). Following Day 22 ep80 CS-010 Sansho Seiyaku kojic acid, confirmed as cosmetic-subseries form-3 information wall excavation #2. This memo records the finding 'origin patent number lies behind an information wall' for the second time, leaving DPMA paper-archive direct inquiry or Beiersdorf direct inquiry as the next action.

Day 22 attempted to excavate CS-002 Allergan Botox origin patent. The DB number US4932936 turned out to be University of Minnesota Twin Cities' 'Method and device for pharmacological control of spasticity' (Dennis D. Dykstra / Abraham A. Sidi co-invention, filed 1988-01-29, granted 1990-06-12) — completely unrelated. Further investigation across multiple secondary sources (Wikipedia Alan B. Scott, Medicine 2023 paper 'Early development history of Botox', ScienceDirect obituary 'Professor Alan B. Scott 1932-2021: The inventor of Botox') confirmed that the Allergan Botox origin patent itself does not exist. Scott's lab patent policy declared items / processes of possible patentability, but the lawyers determined that Scott's 1973 paper (Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol Vis Sci 12: 924-927, 1973) had already publicly disclosed the invention's core — botulinum toxin A injection into extraocular muscles for strabismus correction — voiding patentability, so Scott decided not to file. Without a patent, no pharma company would take over manufacturing. Scott took out a home loan in the 1980s, founded Oculinum Inc., handled production and trials in-house, obtained FDA approval on 1989-12-29 (strabismus and blepharospasm), and sold to Allergan in 1991 (rebranded as Botox). FDA approved Botox Cosmetic for glabellar lines in 2002, growing into a multi-billion-dollar blockbuster. This memo records the second installment of treating 'patent absence' as a primary source in AI Archaeology, structurally identical to Day 10 ep42 PH-004 Köhler-Milstein monoclonal antibody (Nature 1975 paper voided patentability, MRC declined to file, Wistar Institute's derivative US4172124A was peripheral).

Day 22 attempted to excavate CS-010 Sansho Pharma kojic acid skin-whitening origin patent. The number JP S58-118507 handed off from Day 21 turned out to be Lion Corp's 'transparent toothpaste' patent (filed 1982-01-06, disclosed 1983-07-14, Uematsu / Ichikawa co-inventors), unrelated to Sansho Pharma. None of the five public resources we surveyed — Google Patents, Wikipedia, Sansho Pharma's official history page, Kose's research report (after redirect to koseholdings.co.jp), or the Dermed research report — list the origin patent number for Sansho Pharma kojic acid. Confirmed public-history facts: (1) Sansho Pharma discovered kojic acid's tyrosinase inhibition (melanin-synthesis enzyme suppression) in 1975, (2) after 13 years of R&D, in 1988 it became Japan's first quasi-drug whitening active approval, (3) Kose launched 'Kose Whitening Cream XX' in 1990, (4) MHLW issued a notice in March 2003 temporarily suspending kojic acid use in quasi-drugs, (5) on 2005-11-02 the suspension was lifted after additional safety tests showed no problem. J-PlatPat is JS-heavy and authenticated for WebFetch, so the origin patent number identification requires direct query to Sansho Pharma or interactive J-PlatPat search. This memo excavates the 'origin patent number is hard to identify from public web resources' information wall as the first installment.

We added CS-009 'P&G Niacinamide Skin-Whitening Patent US5939082' to candidates.tsv on Day 22 and pulled the primary source from Google Patents. Claim 1 verbatim turned out to be 'a method of regulating mammalian skin pore size,' the independent claim, while the term 'skin lightening agents' in the specification appears only as a list of optional auxiliary components — kojic acid, arbutin, ascorbic acid and derivatives. The widely circulated industry catchphrase 'P&G niacinamide skin-whitening patent' (1) ignores the patent's actual Claim 1 subject (pore size), and (2) confuses niacinamide with the parallel skin-lightening agents list in the specification. The patent's title is 'Methods of regulating skin appearance with vitamin B3 compound,' Original/Current Assignee is Procter and Gamble Co, and inventors are Donald Lynn Bissett / John Erich Oblong / Kimberly Ann Biedermann (the 'Bissett alone' folk wisdom needs correction). Priority 1995-11-06, Filing 1997-04-11, Grant 1999-08-17, expiration 2015-11-06. Day 21 ep76 promised the correct P&G niacinamide skin-whitening patent. The fact-check shows it is not a whitening patent at all — it is a pore-size regulation patent. Day 20-22 cumulative cosmetic-subseries DB corrections reach 49 entries with this note's three additions (inventor count, Claim 1 subject, catchphrase-misreading structural finding).

After ep76 confirmed the candidates.tsv CS-008 'Kojic acid whitening Ajinomoto US4767628' swap, this memo reads US4767628's reality — Imperial Chemical Industries Ltd (ICI, now AstraZeneca)'s Francis G. Hutchinson 'PLA / PLGA × polypeptide drug two-phase sustained-release pharmaceutical composition' patent — at Claim 1 verbatim level and translates it into pharmaceutical delivery context, organizing its position as the core patent of AstraZeneca's Zoladex® goserelin (LH-RH agonist 1-month / 3-month sustained-release implant) and its distant relation to Sculptra PLLA filler (medical aesthetics collagen biostimulator). Decomposes Claim 1 into six elements: (1) polylactide-system matrix (PLA homopolymer or PLA-PLGA copolymer; lactic acid in racemic or optically active form), (2) polylactide content 50% to 99.999% w/w, (3) polylactide viscosity range (benzene-soluble 0.093-0.5; benzene-insoluble 0.093-4), (4) pharmacologically active polypeptide content 0.001% to 50% w/w, (5) polypeptide molecular weight ≥ tetragastrin (four or more amino acid residues, not significantly hydrolyzed under use conditions), (6) two-phase sustained release in aqueous physiological environment (initial diffusion / late matrix degradation). Further organizes the ICI Pharmaceuticals → Zeneca → AstraZeneca lineage and the clinical importance of Zoladex® goserelin (1989 UK / 1990 US approval, currently maintaining $300-500M annual global sales for prostate, breast cancer, endometriosis), and the market scale of successor PLA-PLGA sustained-release products (Lupron Depot, Trelstar, Sandostatin LAR, Vivitrol, Bydureon, etc.). No direct cosmetic relevance, but Sculptra (PLLA filler, US Galderma, collagen biostimulator) widely used in medical aesthetics differs from this only in 'whether the same in vivo PLA / PLLA degradation reaction is used for drug release or collagen induction,' and is added to Day 22+ candidates for **medical aesthetics subseries spin-off** consideration. Patent presumed expired since 2008-08-30 (Grant + 20 years) (USPTO PAIR / litigation records need separate verification); PLA / PLGA × polypeptide sustained-release delivery forms can now be freely incorporated into new generics.

After ep76 confirmed the candidates.tsv CS-007 'Niacinamide whitening patent P&G US5851538' swap, this memo reads US5851538's reality — Advanced Polymer Systems Inc (APS, parent of Microsponge®)'s low-irritation retinol porous microsphere formulation patent — at Claim 1 verbatim level and translates it into cosmetic delivery context. Co-inventors Michael Froix / Masha Pukshansky / Sergio Nacht (Sergio Nacht is an APS co-founder with dermatology / pharmacy [PharmD] background, long responsible for Microsponge® application development). Original Assignee APS Inc, Application 1995-12-29, Grant 1998-12-22, US Patent US5,851,538 A. Claim 1 verbatim: 'A stable pharmaceutical composition for topical administration of retinol consisting of an oil-in-water emulsion comprising, suspended in the emulsion, solid water-insoluble microscopic particles containing a substantially continuous network of pores open to the exterior of the particles and a retinoid composition comprising retinol residing only in the pores, the composition causing lower irritancy when applied than a composition containing the same concentration of retinol in a non-(microscopic particle) formulation.' This memo decomposes Claim 1 verbatim into seven elements: (1) oil-in-water emulsion form, (2) microparticle solid / water-insoluble / microscopic size, (3) continuous pore network, (4) external pore opening, (5) retinol composes the retinoid composition, (6) retinol resides only within the pores, (7) lower irritancy compared to a non-microparticle formulation of the same concentration. It then traces the lineage of five major delivery products in the APS Microsponge® extension (Ortho-McNeil's Retin-A Micro 0.1% gel / Galderma's Differin Gel 0.1% / P&G/J&J Olay Total Effects / Johnson & Johnson RoC Retin-Ox / later 0.5-1.0% retinol face creams). Finally, if this 1998-Grant patent is fully expired (Grant + 20 years = 2018-12 expire), modern free-market retinol high-concentration skincare (The Ordinary Retinol 1%, La Roche-Posay Pure Retinol 0.3, Olay Regenerist Retinol 24, etc.) can freely incorporate Microsponge / Polytrap / Microcapsule delivery forms (other related patents need separate verification via J-PlatPat / USPTO PAIR). Adds to Day 22+ excavation candidates: positioning as cosmetic subseries Phase 2 'delivery patents' candidate, and survey of Microsponge / Polytrap / Microcapsule adoption in modern high-concentration retinol products.

Patents registered in candidates.tsv as CS-007 'Niacinamide (Vitamin B3) whitening patent (P&G) US5851538' and CS-008 'Kojic acid whitening patent (Ajinomoto) US4767628' were retrieved from Google Patents in Day 21 and found to be neither niacinamide nor kojic acid nor whitening patents. CS-007 US5851538 turned out to be 'Retinoid formulations in porous microspheres for reduced irritation and enhanced stability,' co-inventors Michael Froix / Masha Pukshansky / Sergio Nacht, Original Assignee Advanced Polymer Systems Inc (APS, the parent of Microsponge® technology), Application 1995-12-29, Grant 1998-12-22. Claim 1 verbatim covers 'a stable pharmaceutical composition for topical administration of retinol consisting of an oil-in-water emulsion comprising solid water-insoluble microscopic particles containing a substantially continuous network of pores open to the exterior of the particles and a retinoid composition comprising retinol residing only in the pores' — the lineage of Ortho-McNeil's Retin-A Micro 0.1% gel (FDA approval 1997). CS-008 US4767628 turned out to be 'Continuous release pharmaceutical compositions,' sole inventor Francis G. Hutchinson, Original Assignee Imperial Chemical Industries Ltd (ICI, later Zeneca, now AstraZeneca), Application 1987-07-01, Grant 1988-08-30. Claim 1 verbatim covers '50% to 99.999% polylactide (homopolymer of lactic acid or copolymer of lactic acid and glycolic acid) and 0.001% to 50% pharmacologically active polypeptide (molecular weight at least that of tetragastrin, four or more amino acid residues), uniformly dispersed, exhibiting two-phase release in aqueous physiological environment' — the lineage of AstraZeneca's prostate / breast cancer therapy Zoladex® (goserelin, LH-RH agonist 1-month / 3-month sustained-release implant). Neither patent has any connection with whitening, niacinamide, or kojic acid. DB corrections in this note: CS-007 patent number / ingredient / inventor / assignee / use / Claim 1 subject (six items, #36-#41), and CS-008 same six items (#42-#47), totaling twelve. Cosmetic subseries DB corrections across Days 20-21 now total 11 cases / 47 label discrepancies. The finding: cosmetic subseries DB contains a structural mis-pattern of pharmaceutical drug-delivery patents masquerading as cosmetic ingredient patents — a different class of error from Day 20 ep74-75 'cosmetic DB contains a non-cosmetic patent' swaps. Day 22+ tasks: (a) excavate the correct P&G niacinamide whitening patent (candidate US5939082 etc.), (b) excavate the correct kojic acid whitening patent (candidate JP S58-118507 from Sansho Pharmaceutical), (c) establish a number-validity check procedure for the cosmetic subseries DB.

When US3839566, registered in candidates.tsv as 'CS-005 Avobenzone (Parsol 1789) sunscreen patent,' was retrieved from Google Patents, the title turned out to be 'Compositions for topical application to animal tissue and method of enhancing penetration thereof,' with inventors Francis S. Kilmer MacMillan / Warren I. Lyness and assignee Procter & Gamble (P&G). Priority 1970-05-15, Grant 1974-10-01. Claim 1 covers 'a pharmacologically active steroid plus 0.1-10.0% of a C8-C12 aliphatic methyl sulfoxide selected from 8 species (octyl / nonyl / decyl / undecyl / dodecyl / 2-hydroxydecyl / 2-hydroxyundecyl / 2-hydroxydodecyl methyl sulfoxide).' No relation to Givaudan, Hoffmann-La Roche, or avobenzone. This patent is P&G's proprietary delivery technology — an extension of DMSO-class percutaneous penetration enhancers to higher-chain (C8-C12) aliphatic sulfoxides for medical and cosmetic topical formulations. The correct origin patent for avobenzone (butyl methoxydibenzoylmethane, Parsol 1789) is the **1973 Givaudan patent** (Wikipedia / industry reports), with the number unconfirmed at the time of writing. The next excavation step is direct USPTO Patent Public Search using 'Givaudan' / 'butyl methoxydibenzoylmethane' / '1973.' Day 20 cumulative DB corrections updated to 35th by this memo (CS-005 patent-number mix-up); cosmetic subseries accumulated 7 corrections within Day 20 alone (CS-006: 5, CS-004: 1, CS-005: 1).

When DE200619C, registered in candidates.tsv as 'CS-004 Nivea (oil-in-water emulsion) patent,' was retrieved from Google Patents, the title turned out to be 'Bienenkorbkühler' (honeycomb cooler — a motor radiator), the assignee was 'Firma C. Schnewindt in Neuenrade i.W.' (a German mechanical-engineering firm), and the grant date was 1907-01-16. Claim 1 covers a radiator structure of woven tubes and wires sealed at their joints with solder — a complete mechanical engineering patent unrelated to Beiersdorf, Lifschütz, Troplowitz, Nivea, or Eucerit. This memo records the find as a 'failed excavation log' in the same pattern as IR Archaeology #1. Lifschütz's Eucerit manufacturing process ('Eucerinum anhydricum,' 'highly water-absorbent salve bases') was filed in Germany in 1900 and granted as a Deutsches Reichspatent in 1902. Beiersdorf purchased the patent from Lifschütz in 1911, the same year Troplowitz, Unna, and Lifschütz launched Nivea Creme. The correct DRP number is unconfirmed at the time of writing; Beiersdorf's official history and the Eucerin brand history do not state the number, and direct search of the DPMA (German Patent and Trademark Office) archive is the next excavation step. Day 20 cumulative DB corrections: 29-33 from CS-006 (ep73) plus the 34th from this memo (CS-004 patent-number mix-up).

On March 7, 1975, Ruey J. Yu and Eugene J. Van Scott of Temple University Medical School Department of Dermatology filed US Patent 4105782 'Treatment of acne and dandruff.' Filing 1976-09-07, Grant 1978-08-08. Inventors: Yu (first) / Van Scott (co-inventor). Original Assignee: 'Individual' — no record of assignment to Temple University. Claim 1 requires (1) topical application to involved areas of acne or dandruff, (2) at least one of 16 listed α-hydroxy / α-keto / β-hydroxy acids (citric, glycolic, glucuronic, galacturonic, glucuronolactone, gluconolactone, α-hydroxybutyric, α-hydroxyisobutyric, malic, pyruvic, β-phenyllactic, β-phenylpyruvic, saccharic, mandelic, tartaric, tartronic, β-hydroxybutyric), and (3) reaction with ammonia or an organic amine (primary, secondary, tertiary alkylamine; alkanol amine; diamine; etc., C1-C8) to form 'amide and ammonium salts.' Abstract: 'addresses defective keratinization, 1-20% in solutions, lotions, creams, shampoos.' The patent became the claim-level origin of (1) NeoStrata's AHA skincare line (Yu / Van Scott co-founded NeoStrata in 1988), (2) chemical peels (30-70% glycolic acid in clinic), (3) LHA / PHA / gluconolactone derivatives, (4) US FDA's OTC AHA concentration and pH regulation discussions in the 1990s, (5) AHA-formulated quasi-drug products in Korea and Japan. Five DB corrections: (1) inventor order (DB 'Van Scott / Yu' → reality 'Yu first / Van Scott co-inventor'), (2) Original Assignee (DB 'Temple University license' → reality 'Individual / privately held'), (3) use (DB 'AHA peeling' → Claim 1 verbatim 'acne or dandruff treatment'), (4) compound scope (DB 'glycolic acid' → Claim 1 verbatim '16 α-hydroxy / α-keto / β-hydroxy acids'), (5) formulation requirement (DB 'topical application of acid' → Claim 1 verbatim 'reaction product of acid and base required'). Day 20 cumulative DB corrections updated to 29th / 30th / 31st / 32nd / 33rd by this single note.

On December 6, 1984, two researchers at Biomatrix Inc—Endre A. Balazs (Hungarian-born ophthalmologist and biomaterials scientist, founder of the Matrix Biology Institute and former Columbia University faculty) and Adolf Leshchiner—co-filed 'Cross-linked gels of hyaluronic acid and products containing such gels.' The US filing was 1985-03-08, granted as US4636524A on January 13, 1987. Claim 1 covers 'a delivery system for a substance having biological or pharmacological activity, said system comprising a molecular cage formed of a cross-linked gel of hyaluronic acid or a mixed cross-linked gel of hyaluronic acid and at least one other hydrophilic polymer co-polymerizable therewith and having dispersed therein a substance having biological or pharmacological activity and which is capable of being diffused therefrom in a controlled manner.' The Claim 1 verbatim writes 'molecular cage formed of a cross-linked gel of hyaluronic acid,' explicitly requiring the molecular cage of Day 19's 'Cage Patents' axis. The patent became the **patent-claim starting point** for (1) Restylane (Q-Med, 1996 EU approval / 2003 FDA approval), (2) Juvederm (Allergan, 2006 FDA approval), (3) joint-injection drugs Synvisc / Hyalgan (osteoarthritis treatment), (4) the ophthalmic Healon (cataract surgery), and (5) all crosslinked HA fillers used routinely in aesthetic dermatology. Two DB corrections: (1) DB 'Balazs (Columbia University) solo' → reality 'Balazs + Adolf Leshchiner two co-inventors,' and (2) DB 'Columbia University / Matrix Biology Institute assignee' → reality 'Original Assignee Biomatrix Inc / Current Assignee Sanofi Biosurgery Inc' (Biomatrix is the company Balazs co-founded in 1981, distinct from Columbia University). Day 19 cumulative DB corrections: 27th / 28th. This memo retrieves title, inventors, assignees, dates, and Claim 1 from Google Patents, but the full specification (details on crosslinking agents such as divinyl sulfone, formaldehyde, 1,4-butanediol diglycidyl ether; the relationship to Restylane / Juvederm derivative patents) is unread.

On September 23, 1969, in Philadelphia, PA, University of Pennsylvania dermatology professor Albert M. Kligman filed US Patent US3729568 'Acne treatment' as sole inventor. Claim 1 requests a method of 'applying vitamin A acid topically to the affected area in a concentration effective for the treatment of acne and repeating such applications daily, whereby said applications result in the peeling and diffuse redness of the skin treated, and continuing said treatment until the acne has subsided.' The patent was granted April 24, 1973 and expired April 24, 1990. Both original and current assignee are Johnson & Johnson (New Brunswick, NJ). The invention's background includes Kligman and J.E. Fulton's late-1960s clinical research, including trials on inmates at Holmesburg Prison (now criticized as an ethics issue). In 1971, FDA approved Retin-A (prescription tretinoin) for acne vulgaris, backed by this patent. In 1986, Kligman et al. published 'Topical tretinoin for photoaged skin' in J Am Acad Dermatol (not NEJM), first describing histological improvement against photoaging. In 1995, FDA approved Renova (tretinoin 0.05% emollient cream) as the first photoaging-indication drug. Kligman coined 'cosmeceutical' in 1984, popularizing it as a concept that redefines the FDA cosmetic-vs-drug boundary (FDA does not legally recognize this category; tretinoin is treated as a drug because it changes structure/function, prescription only in the US). In Japan, tretinoin is treated as a drug under the Pharmaceutical Affairs Act, prohibited from cosmetic and quasi-drug formulations (only available via personal import). This memo confirms primary URL and Claim 1 retrieval, but the full specification body remains unread, and the Cosmetic Archaeology subseries (Kao / L'Oréal / Nivea sensitive-skin axis) differentiation axis is also addressed. DB corrections (2 items: inventorship, 1986 paper journal) follow the Day 8~15 19-correction series.